Since completing a PhD in Antarctic Biology from the University of Tasmania, Stuart has built up considerable experience of science policy, pharmaceutical R&D, grant funding, IP management, business development and commercialisation in the university and not-for-profit sectors.|
Stuart joined TIA as CEO in 2017. Under his leadership, TIA has focussed investment on the gap between research and development of high-value therapeutics, including pharmaceuticals, biologics, vaccines and cell & gene therapies. He also devised an innovative infrastructure access voucher scheme. He is a graduate of the Australian Institute of Company Directors